Results 31 to 40 of about 8,086 (190)

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer [PDF]

Genes & Cancer, 2014
The fusion between ERG coding sequences and the TMPRSS2 promoter is the most prevalent in prostate cancer (CaP). The presence of two main types of TMPRSS2-ERG fusion transcripts in CaP specimens, Type I and Type II, prompted us to hypothesize that the cumulative actions of different ERG variants may impact CaP development/progression.
Anshu, Rastogi, Shyh-Han, Tan, Ahmed A, Mohamed, Yongmei, Chen, Ying, Hu, Gyorgy, Petrovics, Taduru, Sreenath, Jacob, Kagan, Sudhir, Srivastava, David G, McLeod, Isabell A, Sesterhenn, Shiv, Srivastava, Albert, Dobi, Alagarsamy, Srinivasan   +13 more
openaire   +2 more sources

Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells [PDF]

Nature Communications, 2013
While chromosomal translocations have a fundamental role in the development of several human leukaemias, their role in solid tumour development has been somewhat more controversial. Recently, it was shown that up to 80% of prostate tumours harbour at least one such gene fusion, and that the most common fusion event, between the prostate-specific ...
Euan S, Polson, John L, Lewis, Hamza, Celik, Vincent M, Mann, Michael J, Stower, Matthew S, Simms, Greta, Rodrigues, Anne T, Collins, Norman J, Maitland   +8 more
openaire   +2 more sources

Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis

Nature Communications, 2023
Whether TMPRSS2-ERG fusion and TP53 gene alteration coordinately promote prostate cancer (PCa) remains unclear. Here we demonstrate that TMPRSS2-ERG fusion and TP53 mutation / deletion co-occur in PCa patient specimens and this co-occurrence accelerates ...
Donglin Ding, Alexandra M. Blee, Jianong Zhang, Yunqian Pan, Nicole A. Becker, L. James Maher, Rafael Jimenez, Liguo Wang, Haojie Huang   +8 more
doaj   +1 more source

The molecular basis for ethnic variation and histological subtype differences in prostate cancer. [PDF]

, 2013
Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity and mortality of prostate cancer increase dramatically in several oriental countries including China.
Goldstein, Andrew S, Huang, Jiaoti, Zong, Yang   +2 more
core   +1 more source

Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR [PDF]

, 2013
Prostate cancer (PCa) is a very heterogeneous disease, and there are constraints in its current diagnosis. Serum PSA levels, digital rectal examination (DRE), and histopathologic analysis often drive to overdiagnosis and overtreatment.
Calatrava, Ana, Espinet, Blanca, Fernández-Serra, Antonio, García Casado, Zaida, Gil-Benso, Rosario, López-Guerrero, José Antonio, Rubio, Luis Alberto, Rubio-Briones, José, Salgado, Rocío N.   +8 more
core   +4 more sources

TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas [PDF]

Modern Pathology, 2009
Ductal adenocarcinoma of the prostate is an unusual subtype that may be associated with a more aggressive clinical course, and is less responsive to conventional therapies than the more common prostatic acinar adenocarcinoma. However, given its frequent association with an acinar component at prostatectomy, some have challenged the concept of prostatic
Tamara L, Lotan, Antoun, Toubaji, Roula, Albadine, Mathieu, Latour, Mehsati, Herawi, Alan K, Meeker, Angelo M, DeMarzo, Elizabeth A, Platz, Jonathan I, Epstein, George J, Netto   +9 more
openaire   +2 more sources

SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression [PDF]

, 2015
The ERG gene is fused to TMPRSS2 in approximately 50% of prostate cancers (PrCa), resulting in its overexpression. However, whether this is the sole mechanism underlying ERG elevation in PrCa is currently unclear.
Asara, John M., Beck, Andrew H., Cheng, Liang, Dai, Xiangpeng, Gan, Wenjian, Huang, Jiaoti, Inuzuka, Hiroyuki, Li, Zhen, Liu, Pengda, Lunardi, Andrea, Pandolfi, Pier Paolo, Sun, Yin, Varmeh, Shoreh, Wei, Wenyi, Zhang, Jinfang   +14 more
core   +1 more source

TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma [PDF]

Modern Pathology, 2009
Minute prostatic adenocarcinomas are considered to be of insufficient virulence. Given recent suggestions of TMPRSS2-ERG gene fusion association with aggressive prostatic adenocarcinoma, we evaluated the incidence of TMPRSS2-ERG fusion in minute prostatic adenocarcinomas.
Roula, Albadine, Mathieu, Latour, Antoun, Toubaji, Michael, Haffner, William B, Isaacs, Elizabeth, A Platz, Alan K, Meeker, Angelo M, Demarzo, Jonathan I, Epstein, George J, Netto   +9 more
openaire   +2 more sources

Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.

PLoS ONE, 2015
Gene fusions involving ETS family transcription factors (mainly TMPRSS2-ERG and TMPRSS2-ETV1 fusions) have been found in ~50% of human prostate cancer cases.
Douglas E Linn, Roderick T Bronson, Zhe Li   +2 more
doaj   +1 more source

Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide

Molecular Therapy: Nucleic Acids, 2016
Our purpose was to develop a new pharmacological approach for the treatment of prostate cancer (PCa), the most common neoplasia in men. Recently, we developed siRNA against the fusion oncogene TMPRSS2-ERG found in 50% of patients and showed an ...
Giorgia Urbinati, Isabelle de Waziers, Mateja Slamiç, Tobias Foussignière, Hafiz M Ali, Didier Desmaële, Patrick Couvreur, Liliane Massaad-Massade   +7 more
doaj   +1 more source